Lummy(SZ:300006) Zheng Quan Shi Bao Wang·2025-10-21 12:24Core Insights - Laimei Pharmaceutical reported a revenue of 581 million yuan and a net loss of 45.91 million yuan for the first three quarters, with a third-quarter revenue of 204 million yuan and a net loss of 14.54 million yuan, indicating a reduction in losses year-on-year [2] Product Developments - The company achieved significant progress with multiple products, enhancing its product pipeline and market competitiveness [2] - Laimei received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (0.5g) and registered two other drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml: 30mg) [2][3] Market Performance - Mycophenolate Mofetil is an immunosuppressant used to prevent acute organ rejection in kidney and liver transplant patients, with sales in China's hospital market projected to grow from 32.89 million yuan in 2022 to 60.59 million yuan in 2024 [2] - Nicorandil tablets, used for treating angina, are expected to see sales increase from 676 million yuan in 2022 to 873 million yuan in 2024 [3] - Ketorolac Tromethamine injection, indicated for moderate to severe postoperative pain, is projected to have sales of 2.643 billion yuan in 2022, decreasing to 898 million yuan by 2024 [3] Future Strategy - The company plans to focus on its strengths in niche markets, continue introducing new products, accelerate the market launch of newly introduced products, and enhance its innovation efforts to navigate opportunities and challenges in the pharmaceutical industry [3]